COMMUNIQUÉS West-GlobeNewswire

Dermatology Experts Present Latest Information at 2019 AAD Summer Meeting
25/07/2019
NEW YORK, July 25, 2019 (GLOBE NEWSWIRE) -- The 2019 American Academy of Dermatology Summer Meeting will take place from July 25 to 28 at the New York Hilton Midtown. The meeting will feature the latest information on [...]
Rubius Therapeutics Appoints Kris Elverum as Senior Vice President of Business Development and Strategy
25/07/2019
CAMBRIDGE, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new [...]
Passage Bio Expands Executive Management Team
25/07/2019
Company appoints Jill Quigley, J.D., as Chief Operating Officer and Alex Fotopoulos as Chief Technical Officer PHILADELPHIA, July 25, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV- [...]
Tabula Rasa HealthCare Executive to Present at EXPO.health 2019
25/07/2019
Dr. Alan Stein to Speak on Using Data Science to Mitigate Medication Risk MOORESTOWN, N.J., July 25, 2019 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare (NASDAQ: TRHC), a healthcare technology company advancing the field of [...]
Evelo Biosciences Secures $45 Million Debt Financing from K2 HealthVentures
25/07/2019
CAMBRIDGE, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, [...]
HTG Molecular to Present Corporate Overview at the Canaccord Genuity 39th Annual Growth Conference
25/07/2019
TUCSON, Ariz., July 25, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that John Lubniewski, [...]
Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS
25/07/2019
- Compelling data reported with ADP-A2M4 SPEAR T-cells in synovial sarcoma - - Adaptimmune plans to launch a TCR T-cell therapy in 2022 - PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 25, 2019 (GLOBE NEWSWIRE) -- [...]
Soleno Therapeutics Provides Update on Ongoing DESTINY PWS Phase III Trial of DCCR in Prader-Willi Syndrome
25/07/2019
REDWOOD CITY, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO, the Company or Soleno), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare [...]
Harrow Health to Announce Second Quarter 2019 Financial Results on August 14, 2019
25/07/2019
NASHVILLE, Tenn., July 25, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced it will release second quarter 2019 financial results after the close of trading on Wednesday, August 14, 2019. The [...]
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2019 Earnings and Company Update
25/07/2019
CAMBRIDGE, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and [...]
Matinas BioPharma Receives Qualified Infectious Disease Product (QIDP) and Fast Track Designations From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis
25/07/2019
Fourth QIDP and Fast Track Designations Granted by FDA for MAT2203 BEDMINSTER, N.J., July 25, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, [...]
Kura Oncology to Report Second Quarter 2019 Financial Results
25/07/2019
SAN DIEGO, July 25, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced [...]
Lexicon Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference Call and Webcast on August 1, 2019
25/07/2019
THE WOODLANDS, Texas, July 25, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2019 financial results on Thursday, August 1, 2019 before market opens. Management [...]
Nexstim Plc: Change in Members of the Board Committees
25/07/2019
Company announcement, Helsinki, 25 July 2019 at 2.00 PM Nexstim Plc: Change in Members of the Board Committees Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( "Nexstim" or "Company" ), the targeted neuromodulation company [...]
Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy
25/07/2019
--Independent Data Safety Monitoring Board recommends to continue HOPE-2 study-- --Capricor to resume treating currently enrolled patients-- LOS ANGELES, July 25, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. ( [...]
Amedisys and ClearCare Forge Partnership to Coordinate Home Health Care and Personal Care
25/07/2019
BATON ROUGE, La., July 25, 2019 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), America’s leading independent home health, hospice and personal care company, has signed an agreement with ClearCare, Inc. to create an [...]
Genocea Provides Corporate Update, Including Second-Quarter 2019 Financial Results
25/07/2019
Initiated Part B of Phase 1/2a clinical trial of neoantigen vaccine candidate GEN-009; Plans to present additional GEN-009 immunogenicity data at ESMO 2019 Conference call today at 8:30 am ET CAMBRIDGE, Mass., July 25, [...]
EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code J7314 for YUTIQ® by the Center for Medicare and Medicaid Services (CMS)
25/07/2019
WATERTOWN, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today [...]
Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk
25/07/2019
NEW HAVEN, Conn., July 25, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today that Leslie Norwalk, Esq., [...]

Pages